We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Abbott Faces Calls For Compulsory License For Norvis

Law360 (May 13, 2004, 12:00 AM EDT) -- Abbott Laboratories’ nearly fivefold increase on its AIDS drug Norvis has prompted calls from government officials for a compulsory license for a generic version of the drug before its patent expiration, the Wall Street Journal reported.

In December, Abbott Labs raised the wholesale price for a month's worth of the protease inhibitor Norvir, widely used in small doses to boost the potency of some AIDS combination-drug therapies, to $265 from $54.

The move caused an avalanche of protests from AIDS activists, who have demanded a public...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.